Clinical trial · Observational
The INFLUENCE of Cytoreduction on PRO in EOC
The INFLUENCE of Cytoreduction on Patient Reported Outcomes in Patients With Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach this project aims to better define the value of cytoreduction and to use the knowledge gained to develop more individualized therapy and follow-up. This will be achieved through a translational biomedical research approach. Due to the research group's traditions clinical phenotyping, biomarker identification, and clinical trials will be the focus.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Epithelial ovarial cancer
- description
- Patients primary treated with primary surgery for advanced epithelial ovarian cancer (\> stage IIa) at the participating institutions will be asked to participate.
Primary outcomes (1)
- measure
- Mean Global Health Score
- timeFrame
- 2 years
- description
- Is there a relationship between QOL score and immunologic profiling in biological samples?
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Epithelial ovarian cancer * Stage \> II * ECOG \< II * Treated with primary surgery followed by chemotherapy * Willing to participate and to sign the informed consent Exclusion Criteria: * \< 18 years old * Borderline and non-epithelial ovarian tumors * Stage \< II * Advanced ovarian cancer submitted to neoadjuvant chemotherapy * ECOG 3-4 * Pregnancy * Severe cardiopulmonary disease * Patients participating in QoL intervention studies
References
Publications (0)
Data not yet available